• Awarded Advance and Overseas Finding from AusIndustry for eligible overseas R&D expenditure for NUZ-001 from 2025-2027
• Covers all NUZ-001 development costs, including pre-clinical, manufacturing, regulatory, and clinical programs
• 43.5% cash rebate for eligible R&D expenditure accelerates timelines and provides non-dilutive funding

Neurizon Therapeutics Limited (ASX: NUZ), a clinical-stage biotech company dedicated to advancing treatments for neurodegenerative diseases, has been awarded an Advance & Overseas Finding (AOF) from AusIndustry. This confirms that Neurizon's planned overseas research and development (R&D) expenditure for the 2025, 2026 and 2027 financial years for its lead drug candidate, NUZ-001, is claimable under the Australian Federal Government's R&D Tax Incentive Program. The AOF is binding and means that in addition to eligible Australian R&D expenditure, Neurizon's planned overseas R&D expenditure for NUZ-001 is now eligible for a 43.5% cash rebate. This includes all pre-clinical, manufacturing, regulatory and clinical development expenditure for NUZ-001 in ALS and other neurodegenerative diseases, as well as the HEALEY ALS Platform Trial. The approved AOF supports an expected R&D Tax Rebate of approximately $5.6 million for the 2025 financial year. Neurizon has already secured a loan of $1.5 million against this refund and anticipates receiving a net amount of approximately $4.1 million (before interest and fees) in Q4 CY2025. This Advance and Overseas Finding is a strong validation of Neurizon's development pathway for NUZ-001 and directly supports the company's ability to execute pivotal clinical trials, accelerate timelines, and reduce risk, ensuring momentum in bringing NUZ-001 closer to patients who urgently need new treatment options.

For FY2025, an estimated total R&D Tax Rebate of AUD$5.6 million is expected to be received in Q4 CY2025.